CalAmp is a telematics solutions provider. The company's software applications, cloud services, and intelligent devices collect and assess data including industrial machines, commercial and passenger vehicles, their drivers and contents. The company operates under two reportable segments: Telematics Systems, which provide a series of telematics and stolen vehicle recovery products for the connected vehicle and emerging Internet of Machines marketplace; and Software and Subscription Services, which provide cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open Application Programming Interfaces.

MacroGenics discovers and develops antibody-based therapeutics to modulate the human immune response for the treatment of cancer. The company has a pipeline of product candidates in human clinical testing, including immuno-oncology programs, that have been created using its proprietary antibody-based technology platforms. The company is developing product candidates that target various tumor-associated antigens, including HER2. The company is also developing a franchise of molecules that target programmed cell death protein 1 (PD-1). The company is developing two bispecific DART product candidates that engage PD-1 and lymphocyte-activation gene 3, as well as PD-1 and cytotoxic T-lymphocyte-associated protein 4.